Oral Valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age.
Hilgendorff
A
A
Daiminger
A
A
Dangel
V
V
Kreuder
J
J
Geidel
C
C
Reiss
I
I
Enders
G
G
D000284:Administration, Oral; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D008134:Long-Term Care; D008297:Male; D015997:Neonatal Screening; D056687:Off-Label Use; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir